CMPX - Compass Therapeutics Inc.
Compass Therapeutics Inc. Logo

CMPX - Compass Therapeutics Inc.

https://www.compasstherapeutics.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Beta Bionics ( NASDAQ:BBNX ) , Compass Therapeutics ( NASDAQ:CMPX )
Benzinga • 6 months, 3 weeks ago • score: 0.15
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Benjamin Budish initiated coverage on Blue Owl Capital Inc.
Neutral
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Candel Therapeutics ( NASDAQ:CADL ) , Compass Therapeutics ( NASDAQ:CMPX )
Benzinga • 6 months, 3 weeks ago • score: -0.02
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. CICC analyst Lin Wang initiated coverage on GE Vernova Inc. GEV with an Outperform rating.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.

52W High
$4.08
52W Low
$1.27
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.31
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-8.92
EV/Revenue (<3 favorable)
109.28
P/S (TTM) (<3 favorable)
439.25
P/B (<3 favorable)
6.33
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
11.42%
Institutions (25–75% balanced)
62.64%
Shares Outstanding
171,572,000
Float
100,795,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.45
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.52%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.1839
Previous
0.1802
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025